Artificial intelligence models have shown the potential to decrease disparities in diabetic eye care, personalize management for nAMD treatment and predict outcomes for CRVO.
4D-150 is an intravitreal dual transgene genetic medicine that expresses both aflibercept and an mRNAi sequence that inhibits intracellular expression of VEGF-C.